Several possible studies
Story checked
New US Medicare pricing policies could reshape global pharmaceutical markets (opens in a new tab)
medicalxpress.com · 2026-09-13
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
New US Medicare pricing policies could reshape global pharmaceutical markets
medicalxpress.com · 2026-09-13
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Points somewhere elsementioned without context
10.1016/s0140-6736(26)01555-2
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedA new modeling study published in The Lancet suggests that U.S. Medicare's new Most-Favored-Nation pricing policy could push pharmaceutical manufacturers to raise prices or delay launches.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedFor about three in four medicines studied, the resulting Medicare savings would be worth almost four times that medicine's entire annual sales in the country used to set its price.View evidenceHide evidence
As statedalmost four times
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedThe policy could cut Medicare's prescription drug spending by $5.2 billion (16%) under GLOBE and $6.4 billion (18%) under GUARD during its initial phase.View evidenceHide evidence
As stated$5.2 billion (16%) and $6.4 billion (18%)
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedIf the pricing rules were expanded to all Medicare beneficiaries, the study estimates savings could rise to $21 billion under GLOBE and $25.5 billion under GUARD.View evidenceHide evidence
As stated$21 billion and $25.5 billion
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedThe study estimates that reported confidential deals between manufacturers and the Trump administration could cut the policy's overall Medicare savings, and that for the initial group of 17 manufacturers with announced agreements, projected savings would be cut by 71%.View evidenceHide evidence
As stated71%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedResearchers analyzed 195 patented medicines accounting for $87.9 billion of Medicare annual spending and compared estimated Medicare net prices with prices in 19 reference countries under the proposed rules.View evidenceHide evidence
As stated195 medicines; $87.9 billion; 19 reference countries
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Most-Favored-Nation Benchmarking Versus Value-Based Contracting: Institutional Fit of Pharmaceutical Pricing Tools in the United States, Canada, and the United Kingdom.
Health Services Insights · 2026 · PubMed, Europe PMC
Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements
Value in Health · 2026 · Crossref
Novel Drug Launches in Most-Favored-Nation Countries and Medicare Pricing Benchmarks.
JAMA Health Forum · 2026 · PubMed, Europe PMC, Crossref
Assessment of IPAY 2027 Medicare drug price negotiation maximum fair prices with prices in most-favored nation reference countries.
Journal of Managed Care & Specialty Pharmacy · 2026 · PubMed, Europe PMC, Crossref
VII. Limitations on Most-Favored-Nation Treatment
The Most-Favored-Nation Clause · 1948 · Crossref
And 10 more candidates considered.